Delivery Order SPE2DB22D2206-SPE2DB24FEV01

Award Date 12/26/23
Potential Completion Date 12/27/23
Potential Value $93K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $5,379.45 and is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC has a total potential value of up to...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $13,348.98, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract is a delivery order, with a firm fixed price pricing type, and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $11,552.33, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on December 6, 2022. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business as Amerisourcebergen) and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA), a key agency within the U.S. Department of Defense. The contract, valued at $8,329.05, was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., a major pharmaceutical distribution firm. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical,...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $7,428.83, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a ceiling value of $999,999,999.00 and runs through November 2026. This IDC serves as the primary vehicle for...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., and has a ceiling value of $11,681.09. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November...
This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of Eliquis 5 mg tablets to support military healthcare programs. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The award has a ceiling value of $19,161.56 and runs through May 6, 2024. The contract is a delivery order issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The $10,636.02 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a pharmaceutical distribution company and wholly-owned subsidiary of Cencora, Inc. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Cencora, Inc. with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA) by the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The award, valued at $16,650.77, is a Firm Fixed Price Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive...
This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The $5,699.76 firm-fixed-price delivery order is placed under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FEV01
    Delivery Order

This federal contract award is for the delivery of Eliquis 5 mg tablets to the Defense Logistics Agency (DLA). The contract, valued at $92,811.23, was awarded to AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company.

The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. This IDC serves as the primary vehicle for Cencora, Inc. to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities and veteran healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/13/25, 9:43 AM